Kymera Therapeutics
Elena Ridloff is the Executive Vice President, Chief Financial Officer for Acadia Pharmaceuticals Inc. She joined the company in April 2018 as Senior Vice President, Investor Relations, where she led investor and financial communications activities and since October 2018 has served as Chief Financial Officer. Prior to joining Acadia, Ms. Ridloff was Vice President, Investor Relations at Alexion Pharmaceuticals and served as a member of the Operating Committee. Additionally, Ms. Ridloff was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm serving the life sciences industry. She was also a Managing Director at Maverick Capital, a hedge fund based in New York, and was responsible for investments in the biotechnology, pharmaceutical, medical device, and life science sectors. She currently serves on the Board of Directors of Kronos Bio, Inc.
Ms. Ridloff received her BA in History and Sociology of Science from the University of Pennsylvania. She is also a CFA© charterholder.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Kymera Therapeutics
5 followers
Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.